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Novel ZnO hollow-nanocarriers 
containing paclitaxel targeting 
folate-receptors in a malignant 
pH-microenvironment for effective 
monitoring and promoting breast 
tumor regression
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Ranadhir Basu9, Paul B. Fisher4,7,8, Mahitosh Mandal3 & Amita Pathak1
Low pH in the tumor micromilieu is a recognized pathological feature of cancer. This attribute of 
cancerous cells has been targeted herein for the controlled release of chemotherapeutics at the 
tumour site, while sparing healthy tissues. To this end, pH-sensitive, hollow ZnO-nanocarriers loaded 
with paclitaxel were synthesized and their efficacy studied in breast cancer in vitro and in vivo. 
The nanocarriers were surface functionalized with folate using click-chemistry to improve targeted 
uptake by the malignant cells that over-express folate-receptors. The nanocarriers released ~75% 
of the paclitaxel payload within six hours in acidic pH, which was accompanied by switching of 
fluorescence from blue to green and a 10-fold increase in the fluorescence intensity. The fluorescence-
switching phenomenon is due to structural collapse of the nanocarriers in the endolysosome. Energy 
dispersion X-ray mapping and whole animal fluorescent imaging studies were carried out to show 
that combined pH and folate-receptor targeting reduces off-target accumulation of the nanocarriers. 
Further, a dual cell-specific and pH-sensitive nanocarrier greatly improved the efficacy of paclitaxel 
to regress subcutaneous tumors in vivo. These nanocarriers could improve chemotherapy tolerance 
and increase anti-tumor efficacy, while also providing a novel diagnostic read-out through fluorescent 
switching that is proportional to drug release in malignant tissues.
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Nanomedicine is quickly revolutionizing drug delivery systems (DDS). This is particularly attractive in 
cancer therapy, as localized delivery to the malignancy is increased, while the negative side effects to a 
patients’ healthy tissues are circumvented1. Various nanocarriers have been proposed for DDS, includ-
ing inorganic2,3, composite4–6, polymeric vesicles/micelles7–9, liposomes10 and niosomes11,12. Many of the 
proposed nanocarriers rely on passive accumulation, made possible by the unstable vessel architecture 
of tumors. However, establishing concentrations of chemotherapy in earlier designs of nanocarriers to 
obtain therapeutic responses have fallen short of achieving this objective due to low drug-capacity and 
protracted release profiles13.
Hollow nanocarriers offer substantial internal space in their core to provide high drug-transport 
capacity14,15. Surface modifications of the nanocarrier further enhance the specific targeting to the 
malignant cells and their microenvironment, regulate release kinetics and improve biocompatibility. 
Nanocarriers also provide the opportunity to add diagnostic imaging potential to create ‘theranostics’. 
The assessment of nanocarrier bio-distribution often relies on the addition of fluorescent probes. Yet, 
Genger et al. reported photo-bleaching as a major drawback to organic fluorescent probes16. The emer-
gence of quantum dots as an alternative resolves photo bleaching and offers unique optical fluorescence 
properties. Amongst quantum dots, those comprised of ZnO were extensively studied for photophysical, 
electrochemical and physiological profiles17. The intrinsic fluorescence of ZnO, its biocompatibility as a 
trace element and the ease by which its structure is chemically malleable make it a compelling substrate 
for nanocarrier design of DDS.
Averting nanoparticle agglomeration, metal oxide toxicity and immune reactivity are essential to 
obtain good clinical practices (GCP) of DDS fabrications. To mitigate such risks, wherever possible, natu-
ral biocompatible polymers should be used for structuring and surface functionalization of the DDS. This 
was demonstrated recently by Yang et al., using surface tethering of a biocompatible polymer to achieve 
sustained release of doxorubicin from hollow silica nanoparticles17. Similarly, chitosan is an abundant 
natural biopolymer that can be used as a surface-tethering agent, particularly as new GCP-ready chitosan 
from non-animal sources become available (ex. MycoDev Inc http://mycodevgroup.com). Chitosan is 
recognized for its non-toxic, biodegradable, biocompatible and non-immunogenic nature4. Ideally, water 
soluble polymers are used to deliver lipophilic entities/drugs18. However, the aqueous insolubility of 
chitosan has limited its application in nanocarrier fabrication, stimulating new solution-based research. 
To that end, Pramanik et al., demonstrated that carboxymethylation of chitosan overcomes water insol-
ubility19.
In comparison to healthy tissue, the tumor microenvironment is highly acidic. This is due to the 
nearly 200-fold elevation in glycolysis and lactic acid accumulation from malignant metabolism, cell 
hyperproliferation and poor perfusion from the torturous vasculature20. Sensitizing a nanocarrier to this 
pH variable is a mechanism to reduce chemotherapy accumulation in healthy tissues and to focus it on 
the malignant tumors and their microenvironment. We have now designed a chitosan-ZnO nancoar-
rier that is stable at physiological pH, but collapses to release its drug loaded core in an acidic milieu. 
Click-chemistry renders water-based reactions with no byproducts and is ideal for surface function-
alization21. Neoplasms, particularly of the breast, express high levels of folate receptors20,22. For added 
specificity, our design used click-chemistry to surface conjugate folic acid to facilitate breast cancer 
cell-specificity synergistically with pH for targeting.
Paclitaxel, a member of the taxane drug class, specifically targets microtubule dissociation. It is exten-
sively used for the treatment of human cancers, like breast cancer, malignant lymphoma, osteosarcoma, 
lymphoblastic leukemia and ovarian cancer23,24. However, the dose-limiting issues associated with this 
drug include its poor solubility and toxicity toward normal tissues, which can harm the cardiovascular, 
nervous, gastrointestinal and hepatic systems. In this context, a controlled and focused release of pacl-
itaxel would, in principle, improve the pharmacology and clinical titration of paclitaxel thus, enhancing 
its therapeutic utility.
We have now developed an improved nanocarrier for potential clinical use that addresses several spe-
cific issues important to nanocarrier design: process formulation, biocompatibility, specificity, detectabil-
ity, drug capacity and efficacy. The current design utilizes a combination of pH sensitivity and cell-specific 
targeting to synergistically improve tumor targeting to overcome off-target effects in healthy tissues with 
high metabolisms, such as the hepatic and reticuloendothelial systems. Importantly, as an enhanced 
feature to this design was the increased drug capacity and ability to observe fluorescent photo-switching 
(blue-to-green) as the nanocarrier is targeted to the tumor. We show that this increases the theranostic 
value, not only due to the increased fluorescent accumulation of a nanocarrier at the tumor site, but 
also for determining drug release in proportion to the photo-switching as the nanocarrier breaks down 
intracellularly. Thus, this allows for future advances to enhance titration as a component of personalized 
medicine. Lastly, the developed formulation was achieved using biocompatible, water-soluble carboxym-
ethylated chitosan with naturally occurring zinc-oxide and folic acid via click-chemistry techniques. This 
enhances the potential of the innovation as it improves the processing efficiencies and safety profiles of 
the constituent materials.
Materials and Methods
Materials. Zinc acetate dihydrate (≥ 98%) and dextrose (99.4%) were purchased from Merck Pvt 
Ltd, India. 1-chloropropyl amine hydrochloride (98%), chitosan, propargylamine (98%), and paclitaxel 
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(PAC, ≥97%) were purchased from Sigma Aldrich St. Louis, MO, USA. N-hydroxysuccinimide (NHS, 
98%), N-(3-dimethylaminopropyl)-N-ethylcarbodimide hydrochloride (EDC, 98%), N,N'-Dicyclohexyl 
Carbodimide (DCC, 99%), folic acid (FA, ≥97%), monochloroacetic acid (≥97%), copper sul-
phate pentahydrate (CuSO4. 5H2O, 99.5%), sodium azide (NaN3, 99%), sodium ascorbate (98%), and 
Dimethylsulfoxide (DMSO, 99.2%) were purchased from SRL Pvt Ltd, India. All other chemicals were 
of analytical grade and were used without further purification unless specified (Additional material and 
process details can be found as supplemental information).
Synthesis of carboxymethylated chitosan. Previously, carboxymethylated chitosan (CMC) was 
prepared using chitosan and a monochloroacetic acid modification25. In brief, chitosan and sodium 
hydroxide (10 g each) were suspended in a 100 ml mixture of isopropanol and water (1:1) followed by 
heating at 70 °C for 1 h. Monochloroacetic acid (15 g, dissolved in 20 ml of isopropanol) was added 
drop wise to the resultant mixture for 30 min under vigorous stirring for 4 h at 70 °C. The reaction was 
terminated by adding 70% ethanol (250 ml) and the product was filtered by washing with 90% ethanol, 
dried in a vacuum oven for 24 h at room temperature. Finally, the residual product was suspended in 
acidified ethanol for the formation of carboxymethylated chitosan {1H NMR (400 MHz, D2O, δ ): 1.887 
(CH3, acetamido group of chitosan), 2.99 (CH, carbon 2 of glucosamine ring), 3.5− 4.0 (CH2, carbon 3, 
4, and 6 of glucosamine ring), 4.18 (CH2, carboxymethyl group)}.
Synthesis of 3-azidopropylamine. The azido derivative of 1-chloropropylamine hydrochloride was 
prepared as reported previously26. Briefly, sodium azide (34.6 mmol) was added to the 3-chloropropylamine 
hydrochloride solution (11.5 mmol in 20 ml of water) and heated at 80 °C for 15 h. Subsequently, the 
resultant solution was basified using KOH and extracted with diethyl ether (3 × 25 ml). Additionally, 
the organic phase was dried over magnesium sulfate and concentrated to result in 3-azidopropylamine 
as a colorless volatile oil {1H NMR (400 MHz, CDCl3, δ ): 3.35 (t, J = 6.8 Hz, 2H; CH2-NH), 2.82 (t, 2H, 
J = 6.8 Hz, CH2N3), 1.72 (qn, J = 6.8 Hz, 6.8 Hz, CH2), 1.35 (2H, br s, NH2)}.
Synthesis of an alkyne derivative of folic acid. Folic acid (1 mmol) and DCC (1.5 mmol) was 
dissolved in 10 ml of dry DMSO under inert atmospheric conditions21. Activated carbodimide facilely 
reacts with propargylamine (1.5 mmol) overnight under vigorous stirring in the dark. Lastly, the DCU 
was removed by filtration and the filtrate was precipitated for the desired alkyne derivative of folic 
acid by ice cold diethyl ether{1H NMR (400 MHz, DMSO-d6, δ ): 8.62 (s, PtC7H, 1H), 8.23–8.29 (d, Pt 
C6-CH2NH-Ph 1H, J = 20 Hz), 8.02–8.04 (d, CONHCHCO2H, 1H, J = 8 Hz), 7.63–7.71 (d, Ph-C2H 
and Ph-C6H, 2H), 6.94 (br s, NH2, 2 H), 6.6–6.62 (d, Ph-C3H and Ph-C5H, 2H, J = 8 Hz), 4.45–4.46 (d, 
PtC6-CH2NH-Ph, 2H, J = 4 Hz), 4.34–4.36 (d, PtC6-CH2NH-Ph), 3.79–3.81 (m, -CONH-CH2CtCH, 
2H), 3.06 (t, -CONH-CH2CCH, J = 4 Hz), 2.78 (s, CONH-CH2CCH, 1H), 2.52 (br s, -OH, 1H), 2.3 (m, 
-CH2CO2H), 2.1 (m, -CHCH2CH2, 1H), 1.7 (m, -CHCH2CH2, 1H)}.
Synthesis of Hollow ZnO-nanocarriers. ZnO-nanocarriers were prepared with minor modifica-
tions to that previously described27. Briefly, 1 mmol of zinc acetate was dissolved in 20 ml of ethanol 
under vigorous stirring. To this clear solution, 1 g of carbon nanocarriers was suspended and subse-
quently added with 2 ml of ammonia solution and kept at room temperature for 4 h. By centrifugation, 
the product was collected and washed twice with water and once with ethanol, then dried at 80 °C for 
12 h. The dried product was calcined at 500 °C for 3 h to obtain the hollow ZnO-nanocarriers (HZnO).
Synthesis of carboxyl functional group decorated on ZnO-nanocarriers. Initially, we dissolved 
20 mg of CMC in 5 ml of de-ionized water. To this, 100 mg of HZnO-nanocarriers were added to obtain a 
homogeneous mixture, which became opalescent upon the addition of ethanol, indicating the formation 
of carboxyl functional groups on the HZnO surface.
Synthesis of Azide group functionalized ZnO-nanocarriers. Briefly, HZnO (1 mmol of car-
boxyl groups concentration as measured by NaOH titration) and 1.5 mmol of EDC and NHS were 
dissolved in 10 ml of dry DMSO under inert atmosphere to activate carbodimide and 1.5 mmol of 
3-azidopropargylamine was then added and kept overnight under vigorous stirring. The desired azide 
derivative of chitosan was collected by cold ethanol centrifugation, AZnO.
Conjugation of folic acid on ZnO surface through click chemistry. The alkyne derivative of folic 
acid (1 mmol) and 3-azidofunctionalized ZnO-nanocarriers (100 mg) were suspended in a mixture of 
water and DMSO (1:1). To this solution 110 μ l of sodium ascorbate (1 M) as well as 175 μ l of copper 
sulphate pentahydrate (1 M) was added simultaneously and stirred overnight in the dark. The product 
was separated by centrifugation and washed with ethanol, to finalize the nanocarrier, FCZnO. A similar 
procedure was repeated with paclitaxel (PAC) loading during synthesis to create the final DDS, desig-
nated as FCPZnO.
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Hemocompatibility study. In this study, free PAC, HZnO and FCPZnO-nanocarriers, were individ-
ually suspended in phosphate buffer saline (PBS). Hemocompatibility of these samples were analyzed as 
described previously3. Data is reported as mean ± SD (n = 3).
Cellular uptake studies by epifluorescence microscopy and flow cytometry. Due to the inher-
ent luminescent properties of the nanocarrier they served as an intrinsic fluorescence probe to efficiently 
explore uptake of FCPZnO. Briefly, MCF-7 cells were seeded on glass cover slides in 60-mm plates at 
a density of 1 × 104 cells per coverslip and were allowed to adhere. These cells were then treated with 
FCPZnO for 1, 2, 3, 6 and 12 h at 37 °C, 5% CO2 incubation. Cells were rinsed with PBS three times, 
then fixed with 70% ethanol for 20 min at 37 °C and visualized with an epifluorescence microscope 
(Leica Microsystems GmbH, Germany) equipped with an argon laser using FITC filter (λ Ex 488 nm and 
λ Em 525 nm).
To further validate the intracellular uptake of FCPZnO we assessed fluorescence by flow cytometry. 
MCF-7 and MDA-MB-231 cells seeded at a density of 5 × 104 cells per 60-mm plate were allowed to 
grow to 70% confluence, then treated with FCPZnO at varying time intervals (3, 6 and 12 h). At the 
end of the incubation period, the cells were collected and washed three times with PBS to wash excess 
FCPZnO. Nanocarrier uptake was analyzed in the green FL1 channel (λ Ex 490 nm, λ Em 520 nm) and data 
were collected from >10,000 gated events, then analyzed using the CELL Questpro software program 
(BD Biosciences, USA).
Changes in cell surface potential. The nanocarrier-cell interaction was revealed by determining 
the surface charge of nanocarrier-treated MCF-7 cells using zeta-potential analysis at 25 °C as described 
previously28. Cells were grown and incubated with 100 μ g/ml FCPZnO at varying time intervals from 0 
to 3 h with surface charge monitoring of the FCPZnO with cells.
Cell viability assay. MTT-assay for MCF-7 and MBA-MB-231 cytotoxicity was used, as before29,30. 
Briefly, 100 μ l of 2 × 103 cells were seeded into each well of a 96-well plate. Corresponding PAC, HZnO 
and FCPZnO ranging 0.001–40 nM were added to each well. After 48 h incubation at 37 °C the nanocar-
riers were washed and replaced in 100 μ L of media containing MTT (1 mg/ml); absorbance was meas-
ured at 570 nm.
Cell cycle and apoptosis analysis. Flow cytometry analysis of DNA content was performed to assess 
the cell cycle phase distribution, as described previously31. In brief, both attached and floating cells 
were harvested by trypsinization after a 48 h treatment with the respective IC50 value 14.02 ± 0.6680 to 
8.060 ± 0.4788 nM, respectively, in MCF-7 cells and 11.84 ± 0.5803 to 7.213 ± 0.2847 nM, respectively, in 
MDA-MB-231 cells of native PAC and FCPZnO; then washed twice with PBS (pH 7.2) and incubated 
in 70% ethanol, kept at − 20 °C for overnight fixation. Subsequently, cells were stained for DNA content 
using propidium iodide (PI) and analyzed using CELL Questpro software (BD Biosciences, USA) to 
determine the cell cycle phase distribution and apoptosis.
Morphological analysis. MCF-7 cells were seeded at a density of 6 × 103 on glass coverslips and 
treated without (control), or with PAC, HZnO and FCPZnO for 48 h. Post-incubation, the cells were 
washed three times in 0.1 M cacodylate buffer (pH 7.4) and then fixed in ice-cold 1% OsO4 for 1 h with 
additional EM-processing as described previously4.
For nuclear analysis, cells were grown as above and fixed with formaldehyde, then imaged by fluores-
cence microscopy(Leica DMR, Germany) with DAPI as before32.
In vivo Xenograft Studies. Tumor responses to PAC, HZnO and FCPZnO samples were studied using 
a human breast cancer nude mouse xenograft model. All procedures in animal studies were approved 
and performed in accordance with the institutional animal use and investigation committee at Virginia 
Commonwealth University, School of Medicine, Richmond, VA, USA. Mice were housed and acclima-
tized in a pathogen free environment at the institute animal facility for 1 week prior to injection with 
MDA-MB-231 cells. Exponentially growing MDA-MB-231 cells were collected and 2.5 × 106 cells in Matrigel 
(0.5 mg/mL) were injected subcutaneously (s.c.) in 6–7 week-old female athymic BALB/c (nu+ /nu+ ) 
mice4,33,34. After 6 days, all of the mice were then weighed, the tumors measured using microcalipers 
to calculate tumor volume35. All mice were randomized into four groups, containing 3 mice per group. 
The groups included vehicle (PBS), empty HZnO-nanocarriers, and drug-loaded nanocarriers FCPZnO 
at an equalized dose to the drug-alone paclitaxel (PAC) group {10 mg/kg/day of body weight, i.v. twice 
weekly for 5-weeks}. Weight was monitored to ensure mice did not become cachexic and tumors were 
measured weekly with calipers.
In vivo fluorescence imaging. To ensure traceability in deep tissue, nanocarriers were tagged with 
an IR-Dye 680 to form IR-680-FCPZnO. Mice bearing human MDA-MB-231 tumor xenografts were 
injected either with IR-680 dye or IR-680-FCPZnO. Whole-body optical imaging was performed using 
IVIS Spectrum (Pre-clinical In vivo Imaging System, Perkin Elmer, MA, USA) in fluorescence mode. 
Mice were subjected to anesthesia using inhalant isoflurane (Henry Schein Animal Health, Dublin, OH, 
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USA) prior to and during the imaging procedure. During the period of image acquisition, the mice were 
positioned within the scanner of the imaging platform with IVIS Flow switched on, that regulated the 
flow of oxygen, isoflurane and removed the waste isoflurane gases by anesthesia gas filter unit (f/air) 
(A.M. Bickford Inc., NY, USA).
Immunohistochemical analysis. Analysis of PAC, HZnO and FCPZnO samples were qualitatively 
assessed for proliferation, angiogenesis and apoptosis of human breast cancer xenografted mice tum-
ors using Ki67 and CD31 antibodies and TUNEL nuclei staining. Tissue specimens were processed for 
immunohistochemical analyses as described previously4,36.
Statistical analysis. Statistical analysis was performed by GraphPad Prism 5 software. Data were 
presented using mean ±SD. The statistical significance was determined by using one-way analysis of 
variance (ANOVA). ***P < 0.001 and **P < 0.05 were considered significant.
Results & Discussion. A schematic illustration of ZnO-nanocarrier chemistry is shown in Fig.  1.
The protruded azide groups on ZnO surface and folic acid conjugate through click chemistry on PAC 
loaded ZnO-nanocarriers highlights our material process of making DDS. Initially, carbon spheres were 
suspended in zinc acetate solution, and with the addition of ammonia; resulted in the formation of zinc 
hydroxide on the surface of carbon spheres. Embedding of the hollow natured ZnO-nanocarrier was 
achieved through pyrolysis of carbon.
The phase analysis of ZnO was confirmed by powdered XRD (Fig. 2A) with depicted peaks at 31.7, 
34.5, 36.2, 47.49, 56.58, 62.7, 66.3, 67.9, 69.1, 72.53 and 76.9, and respective reflection crystal planes 
were indexed to be (100), (002), (101), (102), (110), (103), (200), (112), (201), (004) and (202). From 
the above data, we confirmed the hexagonal structure of the sample with P63mc symmetry, which was 
consistent with standard JCPDS file no. 36–145137 and a corresponding crystal structure obtained from 
Rietveld analysis (Fig.  2A inset). The hollow nanocarriers have higher entrapment capacity for greater 
concentrated release of drugs38.
To evaluate the functional groups of the nanocarrier surface following conjugation of folic acid, FTIR 
analysis was performed (Fig. 2B). ZnO-nanocarriers exhibited an intense broad band at the 430–500 cm-1 
region due to the presence of a Zn-O stretching mode. The HZnO depicted clear bands for symmetric 
and asymmetric stretching vibrations of the free carboxylic groups at 1406 and 1633 cm-1, respectively. 
Further, the C–O stretching vibrations resulted in bands at 1023 and 1069 cm-1, while bands at 673 and 
3429 cm-1 represent O-H stretching vibrations and a bridged oxygen (C-O-C) was observed at 1160 cm-1. 
Surface treatment of HZnO by 3-azidopropyl amine through EDC coupling and corresponding func-
tional groups are illustrated in Fig. 2B. However, AZnO showed an asymmetric stretching of N = N = N 
at 2065 cm-1 and amide linkage at 1646 and 1550 cm-1 of amide I and amide II, respectively21.
The successful immobilization of folic acid on AZnO through click chemistry indicates the disappear-
ance of a peak at 2111 cm-1 and the observed characteristic peaks of folic acid at 1603 and 1656 cm-1 in 
the FCZnO sample. Further, FCPZnO generated a distinctive peak at 1736 cm-1 indicating the presence 
of the ester group of PAC. In addition, we also confirmed the successful conjugation of folic acid via 
click chemistry conjugation by 1H NMR and identified peaks in the range of 2.8 to 3.5 ppm ((i)15, (iii)), 
which is due to the presence of glucosamine moieties. An additional peak around 8.12 ppm (iv) is due 
to triazole formation of the click reaction (Fig. S1)26. In addition, we identified aromatic protons of folic 
Figure 1. Schematic representation of the approach used to functionalize folic acid through the click 
chemistry approach for the paclitaxel (PAC) encapsulated ZnO spheres. 
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acid peaks at 8.37 (v), 7.80 (vi), 7.57 (vii), 6.38 (viii), and 6.21 (ix) ppm indicating that a successful con-
jugation of folic acid through click chemistry was accomplished.
TEM imaging revealed that ZnO-nanocarriers produced through basic hydrolysis in the presence of 
carbon spheres under pyrolysis formed an assemblage of ZnO particles encircled over carbon spheres 
(Fig.  2C). The mean size of hollow ZnO-nanocarriers was ~125 nm with a shell thickness of~16 nm 
authenticated by TEM analysis. The architecture of ZnO-nanocarriers was retained following sonication 
indicating its stability, as visualized by TEM micrographs (Fig. 2C ZnO inset). Previously, a similar mor-
phology was observed by Wang et al. from silica-colloidalsomes39.
Tethering and drug encapsulation of nanocarriers resulted in incremental size increases of HZnO 
(180–220 nm) and FCPZnO (200–310 nm) samples. From DLS measurements, FCPZnO showed its 
intense peak at 362 nm (Fig. 2D (i)) under neutral pH (7.2). However, we observed two consecutive peaks 
at 342 and 75 nm (Fig. 2D (ii)) after a 3 h incubation at around pH 5.2 (endo-lysosomal pH). The peak 
at 342 nm signifies the antecedent-state of disorganized nanocarriers at the initial phase, while the peak 
at 75 nm revealed disorganized ZnO particles. Following, prolonged incubation (6 h), the intensity of the 
75 nm peak was amplified, while concomitantly the 342 nm peak disappeared, thus signifying the com-
plete collapse of the hollow nanocarriers (Fig. 2D (iii)). Analogous results were observed in the case of 
HZnO-nanocarriers (data not shown). These results established that these nanocarriers are pH-sensitive. 
Further, these results were supported by TEM studies (Inset of Fig. 2D (ii and iii)). The collapse of the 
hollow natured nanocarriers in an acidic environment provides an additional benefit for payload delivery 
in the acidic environment of malignant cells.
Fluorescence is a constitutive physical property of ZnO (Fig.  3A). Absorbance and fluorescence of 
FCPZnO-nanocarriers were investigated by UV-Vis and fluorescence spectrophotometric studies. In 
agreement with previous literature, the absorption maximum of FCPZnO was 374 nm (Fig. 3A inset)27. 
Moreover, the fluorescence spectra of nanocarriers exhibited blue and green emission maxima at 434 
and 495 nm, respectively. At neutral pH, an emission maximum of 434 nm intensity was higher than that 
of 495 nm. Under acidic conditions, we observed the disappearance of the 434 peak with simultaneous 
proportionate increase of the 495 peak maxima Fig. 3A. This demonstrated the fluorescence-switching 
feature of these nanocarriers. At this pH, augmentation of fluorescence (495 nm) was 10-fold more 
Figure 2. Characterization of nanocarriers (A) XRD pattern of ZnO, (B) FTIR spectrum of ZnO (i), 
HZnO, AZnO (iii), FCZnO (iv), FCPZnO (v). (C) Transmission electron micrographs of ZnO, HZnO and 
FCPZnO. (D) Hydrodynamic radius of FCPZnO samples at pH 7 (i), and 5.2 pH incubation time interval 
3 h and 6 h (iii) Results are representative of three independent experiments.
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compared to neutral condition (Fig. 3A). Furthermore, increased fluorescence intensity correlated with 
a decrease in particle size from 230 nm to 35 nm indicating the disruption of the nanospherical architec-
ture40–42. Thus, the fluorescence intensity is inversely proportional to particle size. Further, fluorescence 
decay studies of FCPZnO revealed two life-time components at 1.27 and 5.42 ns for 495 nm under phys-
iological conditions (Fig. 3B). In acidic pH (5.2), the amplitude and lifetime of the shorter component 
decreases, while the longer component increases. Therefore, the peak maxima at 494 and 434 nm corre-
spond to longer and shorter lifetime components respectively. Similar results were also observed in the 
case of HZnO-nanocarriers.
Thermogravimetric spectrum analysis revealed no disparity in the weight of naked ZnO-nanocarriers 
even in absence of carbon spheres (Fig.  3C). HZnO showed weight loss of 28% at 600 °C due to the 
presence of surface tethered CMC, while FCZnO (i.e., absence of PAC in ZnO-nanocarriers conjugated 
with FA) and FCPZnO (i.e., PAC loaded ZnO-nanocarriers conjugated with FA) displayed reductions in 
weights of 60 and 62%, respectively; the differential weight reduction between the two accounts for the 
successful entrapment of the drug (Fig. 3C). The surface charge of naked nanocarriers was determined 
by zeta potential studies in a wide range of pH conditions (3 to 10). Naked nanocarriers exhibited a 
positive charge of 0.0348 mV at pH 3, any further increase in pH produced a net negative charge with 
the isoelectric point of ZnO at 3.1 (Fig. 3D), whereas HZnO showed an isoelectric point at 4.5. However, 
the surface of FCZnO exhibited a positive charge below the isoelectric point (pH 5.4) but above 5.4 the 
surface charge became negative. Similar results were also observed in the case of FCPZnO, with an isoe-
lectric point 6.4, as the presence of excess positive charge was gained due to drug entrapment. The pos-
itivity of nanocarriers in acidic and neutral environments favor its use in drug delivery applications for 
cancer43 therapy. The encapsulation efficacy of the FCPZnO was determined to be approximately 82%.
Collectively, based on the above results, we hypothesized that healthy negatively charged cells 
at physiological pH would electrostatically repel HZnO-nanocarriers, thus reducing the interaction 
with normal healthy tissues. This could result in a reduction of drug-induced side effects. In the 
circulation, negatively charged nanocarriers become positively charged when encountering an acidic 
Figure 3. (A) Photoluminescence spectra of FCPZnO at a pH 5.2 at various time periods up to 6 h and 
corresponding absorption spectra as an inset, (B) time correlated single photon counting data of emission 
wavelength 495 nm and excitation wavelength 375 nm for HZnO and FCPZnO samples at various pHs 
of 5.2 and 7.4, (C) thermo gravimetric analysis of ZnO, HZnO, FCZnO and FCPZnO samples and their 
corresponding zeta potential in (D), (E) drug release studies, (F) Hemolytic assay of PAC, HZnO and 
FCPZnO. –ve control of 0% lysis (in 1x PBS) and + ve control of 100% lysis (in 1% Triton X-100) were 
employed in this experiment. All the samples (excluding PAC) showing insignificant amount of hemolysis 
with respect to the +ve control. The bars indicate the means ± SD (n = 3).
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tumor microenvironment, thus, manifesting an electrostatic attraction to malignant cells and accumu-
lation of nanocarriers44.
Drug release profile. Regulated drug-release minimizes side effects and avoids toxicity in normal 
cells. Here, the disorganization of nanocarriers favors a pH-regulated release of drug to meet the thera-
peutic index at the tumor site. The drug release profile from FCPZnO at physiological pH was 18% after 
32 h, but at pH 5.2 the release percentage was 74% after just 6 h incubation (Fig. 3E). At an intermediate 
pH of 6, 51% release was achieved by 45 h of incubation. These results were in agreement with our TEM 
and DLS analysis. Additionally, these results are in agreement with the fluorescent-switching intensity 
measures (Fig. S2).
Hemocompatibility study. Assessment for hemolysis is a prerequisite for intravenous administra-
tion to patients. Structural constituents, drugs or physical associations with RBC can negatively impact 
hemostability4,45. Here, PAC alone caused significant hemolysis, likely due to drug toxicity (Fig.  3F). 
However, an equivalent concentration encapsulated PAC as FCPZnO, or the empty nanocarrier HZnO, 
demonstrated very low hemolysis (< 2%), well below the toxicity threshold of < 5%, suggesting both 
integrity of the construct and repulsive forces between the nanocarrier and the RBC membrane at a 
neutral blood pH46.
Assessment of cellular uptake by epifluorescence microscopy and flow cytometry. A 
time-dependent uptake study was carried out using FCPZnO to assess nanocarrier accumulation inside 
tumor cells. The abundant folate receptors present on breast cancer cells augment receptor-mediated 
endocytosis when nanocarriers are surface functionalized with folic acid. Using the intrinsic fluores-
cence property of these nanomaterials, analysis of cellular uptake behavior was performed in MCF-7 
and MDA-MB-231cells by fluorescence microscopy and flow cytometry. Following 1 h incubation, 
cells appeared blue in colour resulting from initial indistinct nanosomal organisation following uptake 
(Fig. 4A). However, cells gradually shifted to bluish green due to endolysosomal nanocarrier disorgani-
sation by the 3 h time point, and then sequentially further shifted into the green spectrum by 6, 12, and 
Figure 4. Cellular uptake studies by flow cytometric and epi-fluorescence microscopic studies. Cells 
treated with FCPZnO (100 μ g/ml) and incubated at varying time intervals. (A) Qualitative analysis of cellular 
localization of nanoparticles in MDA-MB-231 by epi-fluorescence microscopy for 1, 2, 3, 6 and 12 h (scale 
bars: 10 μ m at 20x). (B) Geometric mean analysis of nanocarriers cellular uptake at 3, 6 and 12 h through 
flowcytometry in MCF-7 and MDA-MB-231. Results are representative of three independent experiments.
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24 h. This suggests that uptake of nanocarriers would result in drug release intracellularly and would 
follow the blue-green shift as nanocarriers disorganize.
In flow cytometric analysis, the mean fluorescence intensity (MFI) of MCF-7 and MDA-MB-231 
cells increased progressively with incubation time, peaking at 12 h, which was further supported by the 
summation of multiple geometric mean analyses (Fig. 4B).These observations are in agreement with our 
fluorescence spectrophotometric and decay studies above. Further, zeta-potential studies of MCF-7 cells 
reveal altered surface potentials from control (− 6.3 mV) when incubated with FCPZnO for 30 mins 
(− 6.11 mV), 1 h (− 2.53 mV), 2 h (− 2.42 mV) and 3 h (− 2.36 mV). This change in surface potential 
with respect to control, confirms the uptake of nanocarriers by cellular endocytosis. The cellular uptake 
induced fluorescence shifting from blue to green is expected based on the cell free assessments and the 
expected pH shift in the acidic endo-lysosomal compartments47.
Cytotoxic effects of PAC and FCPZnO on breast cancer cells. To evaluate the in vitro 
anti-proliferative effect of PAC, HZnO and FCPZnO-nanocarriers, MTT dye reduction assays were per-
formed and mitochondrial function was assessed. After a 48 h incubation of cells with PAC, HZnO and 
FCPZnO, significant growth suppression was observed with drug (r = − 0.461, P < 0.05). PAC at 35 nM 
concentration exhibited < 25% growth inhibition, while at an equivalent concentration, FCPZnO signif-
icantly decreased cell proliferation to < 5%, likely as a result of intracellular endo-lysosomal release of 
PAC (Fig. 5A,B). The IC50 values of PAC and FCPZnO were found to decrease from 14.02 ± 0.6680 to 
8.060 ± 0.4788 nM, respectively in MCF-7 cells and 11.84 ± 0.5803 to 7.213 ± 0.2847 nM, respectively in 
MDA-MB-231 cells. The FCPZnO demonstrated a significantly higher proliferation inhibitory effect as 
compared to PAC. This is likely a result of both an enhanced uptake due to folate receptor endocytosis 
and intracellular release within the acidic endo-lysosome.
Figure 5. Proliferation assays after PAC, HZnO and FCPZnO treatment in (A) MCF-7, (B) 
MDA-MB-231 cells was measured using MTT assays. (C) Apoptotic activity of control, PAC, HZnO 
and FCPZnO-nanocarriers on MCF-7 and MDA-MB-231 cells by phase distribution study. Results are 
representative of three independent experiments.
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DNA content analysis. The effect of PAC, FCPZnO and drug-free nanocarriers on MCF-7 and 
MDA-MB-231 DNA content distribution was analyzed for cell cycle status and sub-G apoptosis (Fig. 5C). 
Both PAC and FCPZnO demonstrated reduced proliferative states and large increase in sub-G apoptosis. 
The anti-proliferative efficacy of FCPZnO was greater in MCF-7 than MDA-MB-231. However, there was 
approximately 10% more total apoptosis in FCPZnO treated in both MCF-7 and MDA-MB-231cells, 
as compared to PAC alone. HZnO-nanocarriers exhibited negligible effects on the cells. These results 
indicate that FCPZnO, probably due to internalization by folate receptor mediated endocytosis, is more 
efficacious than PAC alone in vitro.
Morphological analysis. To assess the cytotoxic effects of PAC and FCPZnO in MCF-7 and 
MDA-MB-231 cells, SEM and DAPI staining were performed. Cell morphology by SEM demonstrated 
complete loss of cellular cytoskeleton assemblies as revealed by the absence of cellular protrusions and 
thickening of the cell body in PAC treated cells, and this was observed more often in FCPZnO treated 
MCF-7 cells (Fig. 6A).
Control and HZnO-nanocarriers showed only rarely condensed nuclei, typical of cells in vitro, where 
a majority of cells show large, flattened nuclei with clear nucleoli (Fig. 6B). Early indications of apoptosis 
were observed in PAC and to a greater degree in FCPZnO by DAPI analysis of nuclear morphology. 
Nuclei were mostly condensed, indicative of DNA fragmentation. Further, virtually no nucleoli were 
observed in FCPZnO nuclei.
In vivo fluorescence imaging. To ascertain whether the nanocarrier accumulates efficiently in tum-
ors, we tagged FCPZnO with IR-680 nm dye prior to intravenous delivery in BALB/c (nu+ /nu+ ) mice 
with human MDA-MB-231 breast cancer xenografts. IR680-FCPZnO (5 mg/kg body wt.) was injected 
Figure 6. (A) Scanning electron microscopic images of MCF-7 cells treated with control, HZnO (equivalent 
to weight of the PAC nanoformulation), PAC (IC50) and FCPZnO (IC50) for 48 h. In control cells, healthy 
filopodia and lamellipodia of MCF-7 cells are observed while truncated cytoplasmic extensions (lamellipodia 
and filopodia) in PAC and FCPZnO are visualized. (B) Nuclear morphological analysis of Control, HZnO, 
PAC and FCPZnO treated MCF-7 and MDA-MB-231 cells by DAPI staining (epi-fluorescence microscopic 
image at 20x and scale bars: 10 μ m). Results are representative of three independent experiments.
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systemically by tail vein injection, and the mice were imaged over time using an in vivo imaging system 
(IVIS Spectrum) in fluorescence mode. In vivo Fluorescence imaging (FLI) was done using a spectral 
unmixing approach to eliminate or reduce tissue auto-fluorescence. The composite figure shows the net 
fluorescence due to IR680 dye bound with FCPZnO with subtracted auto-fluorescence from the tissue 
(Fig. 7A). Sequential observations at different time points revealed an initial systemic bio-distribution, 
but with intense signals developing over time that were clearly associated with the subcutaneous tum-
ors (Fig. 7A). These results substantiate our in vitro cellular data and support a targeted delivery of the 
FCPZnO in established tumors in vivo. Thus, we conclude that the nanocarriers accumulated at the 
tumor site due to a combination of preference for folate surface functionalization of the breast cancer 
cells and the charge repulsion of the nanocarriers to healthy tissues.
Effective role of FCPZnO in reducing MDA-MB-231 xenograft tumors in nude mice. In vitro 
results suggested equal or better anti-proliferative and cytotoxic effects using therapeutic doses of pacl-
itaxel delivered by FCPZnO. Based on the in vivo tracing studies, FCPZnO is indicated to accumulate 
intra-tumorly within hours of delivery (Fig.  7A). Follow-up studies of tumor volume and mass how-
ever, clearly demonstrated more than 3-fold greater efficacy in tumor regression favouring the FCPZnO 
delivery compared to an equal dose of PAC in human MDA-MB-231 breast cancer xenografts (Fig. 7B, 
C and D). A slight but significant reduction in tumor mass was observed in HZnO treated animals; 
Figure 7. Regression of MDA-MB-231 tumor xenografts in mice treated with FCPZnO and PAC. (A) In 
vivo real-time images of IRDye 680-labeled FCPZnO compared to control (IRdye-680). (B) Drug treatment 
groups received PAC (10 mg/kg, i.v.), equivalent dose of PAC in nanoformulation (10 mg/kg, i.v.), and 
equivalent weight of nanocarrier (i.v.). Tumor volumes in the FCPZnO group were significantly diminished 
in comparison with free PAC at 35 days after treatment (P < 0.05). (C) Tumor volume (D) Tumor mass (E) 
spectral shift of tumor sections of FCPZnO-treated mice (a and b). (F) FESEM image of tumor cross section 
area for EDX elemental mapping of corresponding sample zinc (yellow), oxygen (green) and carbon (red) 
and corresponding EDX spectra.
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whether this is due to established low zinc bio-availability in malignant tissue remains to be deter-
mined. To confirm the accumulated presence of FCPZnO, tumors were analysed by detailed spectral 
mapping using energy-dispersive X-ray (EDX) spectroscopy (Fig. 7E (a and b)). EDX mapping revealed 
the presence of zinc (yellow), oxygen (green) and carbon (red) elements within the tumor and its corre-
sponding morphology (Fig. 7F) was determined through FESEM for corresponding spectra. To establish 
whether the combination of pH-sensitive uptake with folate-receptor targeting increased the nanocarrier 
accumulation in the tumor site we compared Zn accumulation between equal sections of HZnO and 
ZCPZnO animals (Fig. 8 (A,B)). Further, to determine whether the additional folate targeting prevented 
any aberrant off-targeting of other organs we also examined non-tumor tissues. The addition of folic acid 
targeting, nanocarrier accumulation in the tumor site increases by ~30%, whereas it reduces off-target 
accumulation in the liver and spleen by > 80%. The combined results establish a strong in vivo connec-
tion for a favoured accumulation of FCPZnO regulated drug release by nanocarrier disruption in the 
acidic tumor microenvironment for greater tumor regression and reduced off-target accumulation due 
to pH sensing alone.
Further, we assessed the effects of FCPZnO-nanocarriers on proliferation, and angiogenesis by Ki-67 
(a marker of cellular proliferation), and CD31 (a marker of angiogenesis), respectively on mice xeno-
graft tumors. PAC and FCPZnO-nanocarrier-treated tumors showed reduced expression of Ki 67 and 
CD31 in comparison to control (Supplemental Information), which is consistent with previous reports 
using the native drug48. Control tumors prominently showed hypercellular areas with elevated Ki67 and 
CD31expression, while HZnO treated tumors were minimally affected. This is in contrast to FCPZnO 
treatments, demonstrating reduced cellular proliferation and angiogenesis. This can be attributed to the 
effect of nanocarrier delivered PAC.
Figure 8. (A) Tissue sections of organs from mice treated with HZnO and FCPZnO were subjected to EDX 
mapping analysis for assessing retention ability of Zn nanocarrier. Compared Zn EDX elemental mapping 
with HZnO and FCPZnO samples treated with mice of various organs like tumor, kidney, liver, lung, 
spleen and heart (B). The changes were even more prominent when animals were treated with FCPZnO 
nanocarriers. Results are representative of three independent experiments.
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Conclusions
Here we establish a ‘theranostic’ nanocarrier engineered with biocompatible substrates that show pref-
erential bioaccumulation and cancer-cell uptake by surface functionalization with folic acid, which 
are capable of regulated unloading of chemotherapy in the acidic, malignant microenvironment. 
This report is the first to document disruption of hollow ZnO-nanocarriers that show parallel drug 
release with a fluorescence reporting mechanism. The potential clinical translatability of our fluores-
cent photo-switching is a unique advantage in the design or our nanocarrier, as it could provide a 
diagnostic-based titration of chemotherapy and opportunities for future patient-tailored therapy in 
personalized medicine. The use of click-chemistry is an ideal mechanism to advance cancer-specific 
surface functionalization, so as to provide broader off-the-shelf potential for the design of novel nan-
otherapeutics more specifically, for different cancer types. Using a carbon-based template, calcina-
tions and a soluble chitosan derivative ensures stability and biocompatibility, with significantly greater 
drug-load capacity to achieve strong anti-tumor effects using a practical and achievable dosing regi-
men; all with reduced side-effects by preventing drug accumulation in other organs. In particular for 
chemotherapeutic agents, such as paclitaxel that display negative off-target side effects, a controlled in 
vivo release that provides higher tumor site concentrations holds significant potential to enhance the 
therapeutic efficacy of chemotherapy. Achieving greater therapeutic control to regress tumors by using 
site-directed means of release, significantly de-risks drugs and doses that would otherwise compromise 
healthy tissues. Overall, we are encouraged by this ‘smart-targeting of chemotherapy’ for its overall 
promise to improve the quality of life, recovery and outcome of patients with cancers of the breast, 
and potentially other organs.
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